The effect of different dosages of the V2R antagonist in a PKD1 knockout mouse model for ADPKD at different stages of the disease was investigated and the results showed that initiation of V2R antagonist at the advanced stage of ADPKD lacked reno-protective effects and had less pronounced physiologic effects than early initiation. This evidence concerns the gene AVPR2 and autosomal dominant polycystic kidney disease.